The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: CART Therapy in Digestive System Tumors
Official Title: Chimeric Antigen Receptor T Cells (CART) Therapy in GUCY2C Positive Digestive System Tumors
Study ID: NCT04780529
Brief Summary: Chimeric Antigen Receptor T Cells (CART) Therapy in GUYC2C postive Digestive system tumors, include colorectal cancer, gastric cancer, liver cancer, pancreatic cancer, adenocarcinoma of esophagus, cancer of the esophagogastric junction. Ict-gc is an open, single-center study to evaluate the safety and efficacy of CAR-T-targeted therapy in patients with advanced gastrointestinal tumors.
Detailed Description: The primary objective of phase 1 is to evaluate the safety of CART regimens. The primary objective of phase 2 is to evaluate the efficacy of CART, as measured by objective response rate in subjects with colorectal cancer. Secondary objectives will include assessing the safety and tolerability of CART and additional efficacy endpoints.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui provincial cancer hospital, Hefei, Anhui, China
Name: Yifu he
Affiliation: Anhui Provincial Cancer Hospital
Role: PRINCIPAL_INVESTIGATOR